![美銀:Q3建議買入這9隻股票,還有一隻股票不要碰!](https://i-invdn-com.investing.com/news/LYNXNPEC5715Z_S.jpg)
注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Inozyme Pharma Inc是一家臨床罕見病生物製藥公司。該公司專注於開發影響脈管系統、軟組織和骨骼的異常礦化疾病的治療方法。其還致力於開發一種治療外核苷酸焦磷酸酶/磷酸二酯酶1(ENPP1)和ATP結合盒亞家族C成員6(ABCC6)缺陷的罕見遺傳疾病的療法。該公司的主要候選產品INZ-701是一種可溶性、重組或基因工程融合蛋白,旨在糾正ENPP1和ABCC6缺陷導致的礦化途徑缺陷。其INZ-701正處於治療ENPP1缺乏症和ABCC6缺乏症的I/II期臨床試驗中。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Robert Terkeltaub | - | - | Member of Scientific Advisory Board |
Douglas A. Treco | 66 | 2020 | CEO & Chairman |
Axel Bolte | 52 | 2015 | Co-Founder, Senior Advisor & Director |
Frank Rutsch | - | - | Member of Clinical Advisory Board |
Edward Y. Skolnik | - | - | Member of Scientific Advisory Board |
Thomas O. Carpenter | - | - | Member of Clinical Advisory Board |
Yves Sabbagh | - | 2020 | Chairman of Scientific Advisory Board & Senior VP |
W. Charles O’Neill | - | 2021 | Member of Scientific Advisory Board |
Jouni Uitto | - | 2021 | Member of Scientific Advisory Board |
Paul B. Yu | - | 2021 | Member of Scientific Advisory Board |
Reinaldo M. Diaz | 70 | 2017 | Lead independent director |
Joseph P. Schlessinger | 79 | 2015 | Member of Scientific Advisory Board |
Michael A. Levine | - | - | Chairperson of Clinical Advisory Board |
Lynne Marie Sullivan | 58 | 2020 | Independent Director |
Sarah Bhagat | 37 | 2019 | Independent Director |
Robert L. Hopfner | 51 | 2018 | Independent Director |
Edward T. Mathers | 64 | 2017 | Independent Director |
Martin William Edwards | 68 | 2017 | Independent Director |
Demetrios Braddock | - | - | Co-Founder, Scientific Founder, Member of Scientific Advisory Board & Board Observer |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核